Tests image guidance during radiotherapy for lung cancer
Tests whether tumour tracking without implanted markers works during lung cancer radiotherapy in adults.
Plain-language title generated from the registry record
Registry title: Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging
Key facts
- Where
- Melbourne, AustraliaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having external beam radiotherapy for early lung cancer (Stage I NSCLC) or up to 3 lung metastases. It tests markerless tumour tracking.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage I non-small cell lung cancer proven by tissue exam, or 3 or less lung metastases from a non-blood cancer. Tumour 1 cm (0.4 in) to 5 cm (2 in) in any direction. Tumour centre within 10 cm (3.9 in) of the top of the diaphragm.
- Earlier treatment
- Cannot have had high-dose radiotherapy to the chest before. Cannot have had cytotoxic chemotherapy within 3 weeks of starting treatment or during treatment. Cannot have had targeted drugs within 7 days of starting treatment or during treatment.
Main reasons for not taking part
- Low breathing performance, as judged by the doctors
- Previous high-dose chest radiotherapy
- Less than one fiducial marker placed in the lung
- Markers more than 9 cm (3.5 in) from the tumour centre
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Where in Australia
- Alfred HealthMelbourne, AustraliaContact: Carole OwensTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Sydney
- Trial code
- NCT04086082
- Record updated
- 20 May 2026
- Original description
This trial will investigate the feasibility of the Markerless Tumour Tracking technology.Read full original descriptionShow less
MAGIK: Using Implanted Markers to Determine the Feasibility of Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging: A Phase I Interventional Study of Lung Cancer Radiotherapy
This trial will investigate the feasibility of the Markerless Tumour Tracking technology.
Inclusion: Is willing to comply with all trial procedures and intends to provide written Informed Consent for participation in this trial; Patients undergoing external beam radiotherapy; Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less); MRI/4D-CT prior to insertion of fiducial markers; Patient must be able to have fiducial markers placed in the lung (if on anticoagulants, must be cleared by LMO or cardiologist); ECOG performance status 0-2; A maximum of three metastases to the lung from any non-haematological malignancy. Multiple metastases will be treated separately; 1 cm ≤ Tumour diameter in any dimension ≤ = 5 cm; The distance between the tumour centroid and the top end of the diaphragm is <=10 cm.
Exclusion: Previous high-dose thoracic radiotherapy; Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor modulators); Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of commencement of treatment, or concurrently with treatment; Patient has low respiratory performance as evaluated by the physicians; Less than one fiducial marker implanted in the lung; Fiducial markers are too far from the tumour centroid (>9 cm); Women who are pregnant or lactating; Unwilling or unable to complete quality of life questionnaires.